Sunesis Pharmaceuticals (SNSS) Misses Q4 EPS by 1c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $600 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Kepler Cheuvreux Starts Swiss Re (SREN:SW) (SSREY) at Reduce
• Kepler Cheuvreux Starts Hannover Rueck SE (HNR1:GR) (HVRRF) at Hold